Oss, Netherlands

Pedro Manuel Grima Poveda

This inventor holds 2 USPTO granted patents. Top assignee: N.v. Organon. Active years: 2011.


% Patents Active = 100.0

Average Co-Inventor Count = 3.0

ph-index = 1


Company Filing History:


Years Active: 2011

Loading Chart...
2 patents (USPTO):Explore Patents

Title: Pedro Manuel Grima Poveda: Innovator in Fertility Treatments

Introduction

Pedro Manuel Grima Poveda is a notable inventor based in Oss, Netherlands. He has made significant contributions to the field of medicinal chemistry, particularly in the development of treatments for infertility. With a total of 2 patents, his work focuses on innovative compounds that activate FSH receptors, which are crucial for fertility.

Latest Patents

His latest patents include the invention of 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydroquinoline derivatives as medicaments for the treatment of infertility. This invention relates to a specific derivative that acts as a potent FSH receptor activator, which can be utilized in controlled ovarian hyperstimulation and IVF procedures. Another patent involves similar derivatives that are designed for the treatment of infertility, detailing various substituents and their pharmaceutical applications.

Career Highlights

Pedro is currently associated with N.V. Organon, a company known for its focus on women's health and fertility solutions. His work at Organon has allowed him to contribute to groundbreaking research and development in the field of reproductive medicine.

Collaborations

He has collaborated with notable colleagues such as Cornelis Marius Timmers and Willem Frederik Karstens, enhancing the scope and impact of his research through teamwork and shared expertise.

Conclusion

Pedro Manuel Grima Poveda stands out as an influential inventor in the realm of fertility treatments, with his innovative patents paving the way for advancements in reproductive health. His contributions continue to have a significant impact on the field.

Profile summary based on public USPTO records.
Please report any incorrect information to [email protected]
Loading…